Related Experiment Video
Updated: Sep 17, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Electrocardiographic changes in QTc interval and other parameters associated with osimertinib therapy
Yilin Pan1,2, Kexin Peng1, Yichuan Jiang3
1Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Changchun, China.
Introduction:
Osimertinib, a third-generation EGFR-TKI, is approved for the first-line treatment of EGFR-mutated advanced NSCLC and for T790M-positive NSCLC after progression on previous EGFR-TKI therapy. Osimertinib is associated with cardiotoxicity, including severe QT interval prolongation, which necessitates detailed evaluation due to its increasing use.
Methods:
This retrospective, single-center study conducted at Jilin University China-Japan Union Hospital evaluated electrocardiographic changes with EGFR-mutated NSCLC treated with osimertinib. The study consecutively included 102 patients diagnosed with NSCLC at the China-Japan Union Hospital of Jilin University from August 1, 2019, to December 31, 2022. Among them, 41 patients who had both pre- and post-treatment ECG records while receiving osimertinib (80 mg daily) were analyzed. ECG parameters such as heart rate, PR interval, QRS duration, QRS axis, and QT intervals were manually calculated and analyzed.
Results:
The study population had a mean age of 68.56 ± 8.73 years, comprising 46.34% males. Significant changes were observed in the QTc Bazett interval (P < 0.0001), QTc Fridericia interval (P = 0.0002) and QRS axis (P = 0.0387) post-treatment. QT interval prolongation was significant (McNemar test P = 0.0039), with both QTc Bazett and QTc Fridericia intervals showing notable prolongation. However, the changes in heart rate, PR interval, and QRS duration were not statistically significant.
Conclusion:
This study comprehensively investigates the electrocardiographic changes before and after osimertinib treatment in patients with EGFR-mutated NSCLC. The significant prolongation of QTc intervals underscores the need for rigorous ECG monitoring to mitigate potential cardiotoxicity.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Electrocardiogram
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Correlation between ECG and Cardiac Cycle
A cardiac action potential originates in the SA node and spreads throughout the atria and the AV node in approximately 0.03 seconds. This results in the P wave in an ECG and triggers atrial contraction. The action potential is then briefly slowed at the AV node, allowing the atria to contract and fill the ventricles with blood before...

